D.A. Davidson & Co’s Ironwood Pharmaceuticals IRWD Stock Holding History

D.A. Davidson & Co’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-119	Closed	-$1K	–	1536
2017 Q2	$1K	Hold	119	–	–	﹤0.01%	2331
2017 Q1	$1K	Hold	119	–	–	﹤0.01%	2297
2016 Q4	$1K	Hold	119	–	–	﹤0.01%	2399
2016 Q3	$1K	Buy	+119	New	+$1.39K	﹤0.01%	2336

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

D.A. Davidson & Co's IRWD Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2017, closing a stake of 119 shares — an estimated $1K sold.

D.A. Davidson & Co first reported a position in IRWD in Q3 2016 and held it in 4 quarters. The position peaked at $1K in Q2 2017. 149 funds tracked by Wall St. Rank hold IRWD as of Q3 2017.

D.A. Davidson & Co reported no remaining Ironwood Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 119 Ironwood Pharmaceuticals shares in Q3 2017, an estimated $1K.
D.A. Davidson & Co first reported a position in Ironwood Pharmaceuticals in Q3 2016 and held it in 4 quarters.
D.A. Davidson & Co's Ironwood Pharmaceuticals position peaked at $1K in Q2 2017.
149 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.